ADR Biomedical Holdings Inc. (TYO:3750)
Japan · Delayed Price · Currency is JPY 791.00
-2.00 (-0.25%)
Aug 6, 2026, 2:14 PM JST
ADR Biomedical Holdings Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | -397 | -2,152 | -1,011 | -1,166 | -65 |
Depreciation & Amortization | - | 49 | 253 | 330 | 320 |
Loss (Gain) From Sale of Assets | 20 | 1,210 | -351 | 205 | - |
Loss (Gain) From Sale of Investments | - | 65 | - | - | -85 |
Other Operating Activities | -23 | 109 | -110 | -120 | -97 |
Change in Accounts Receivable | -5 | 51 | - | - | - |
Change in Inventory | -13 | 58 | 15 | 88 | 211 |
Change in Accounts Payable | 1 | -3 | - | - | - |
Change in Other Net Operating Assets | -367 | -374 | 52 | 624 | -471 |
Operating Cash Flow | -784 | -987 | -1,152 | -39 | -187 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | - | -8 | -17 | -158 | -180 |
Sale of Property, Plant & Equipment | 2,944 | 25 | 8,290 | - | - |
Cash Acquisitions | - | - | -1 | - | -212 |
Divestitures | - | 3 | 1 | 198 | - |
Investment in Securities | - | - | 450 | -323 | 77 |
Other Investing Activities | 35 | 2 | -34 | - | 99 |
Investing Cash Flow | 2,979 | 22 | 8,689 | -283 | -216 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | 400 | 300 | 220 | 500 | - |
Long-Term Debt Issued | - | - | - | 2,540 | 250 |
Total Debt Issued | 400 | 300 | 220 | 3,040 | 250 |
Short-Term Debt Repaid | -300 | -70 | -650 | - | - |
Long-Term Debt Repaid | -2,348 | -53 | -5,605 | -2,800 | -538 |
Total Debt Repaid | -2,648 | -123 | -6,255 | -2,800 | -538 |
Net Debt Issued (Repaid) | -2,248 | 177 | -6,035 | 240 | -288 |
Issuance of Common Stock | - | - | - | - | 258 |
Other Financing Activities | -73 | -6 | -1,137 | 54 | 65 |
Financing Cash Flow | -2,321 | 171 | -7,172 | 294 | 35 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Foreign Exchange Rate Adjustments | -2 | - | - | - | - |
Miscellaneous Cash Flow Adjustments | -2 | 12 | - | - | - |
Net Cash Flow | -130 | -782 | 365 | -28 | -368 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -784 | -995 | -1,169 | -197 | -367 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -1568.00% | -815.57% | -74.94% | -9.19% | -27.49% |
Free Cash Flow Per Share | -87.81 | -111.44 | -130.49 | -22.06 | -41.56 |
Levered Free Cash Flow | -452.13 | -662.63 | -326.75 | 1,502 | 2,879 |
Unlevered Free Cash Flow | -440.88 | -611.38 | -231.13 | 1,582 | 2,937 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 22 | 76 | 157 | 120 | 90 |
Cash Income Tax Paid | 18 | -102 | 107 | 3 | 7 |
Change in Working Capital | -384 | -268 | 67 | 712 | -260 |